Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

EKSO vs DBVT vs ALKS vs IRBT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
EKSO
Ekso Bionics Holdings, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$29M
5Y Perf.-79.5%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-56.7%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+106.1%
IRBT
iRobot Corporation

Furnishings, Fixtures & Appliances

Consumer CyclicalNASDAQ • US
Market Cap$2M
5Y Perf.-99.9%

EKSO vs DBVT vs ALKS vs IRBT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
EKSO logoEKSO
DBVT logoDBVT
ALKS logoALKS
IRBT logoIRBT
IndustryMedical - Instruments & SuppliesBiotechnologyBiotechnologyFurnishings, Fixtures & Appliances
Market Cap$29M$1712.35T$5.90B$2M
Revenue (TTM)$12M$0.00$1.56B$547M
Net Income (TTM)$-16M$-168M$153M$-209M
Gross Margin52.9%65.4%22.0%
Operating Margin-134.1%12.3%-29.5%
Forward P/E24.8x
Total Debt$3M$22M$70M$227M
Cash & Equiv.$1M$194M$1.12B$134M

EKSO vs DBVT vs ALKS vs IRBTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

EKSO
DBVT
ALKS
IRBT
StockMay 20May 26Return
Ekso Bionics Holdin… (EKSO)10020.5-79.5%
DBV Technologies S.… (DBVT)10043.3-56.7%
Alkermes plc (ALKS)100206.1+106.1%
iRobot Corporation (IRBT)1000.1-99.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: EKSO vs DBVT vs ALKS vs IRBT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Ekso Bionics Holdings, Inc. is the stronger pick specifically for dividend income and shareholder returns. DBVT also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
EKSO
Ekso Bionics Holdings, Inc.
The Income Pick

EKSO is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 0 yrs, beta 2.02, yield 0.8%
  • 0.8% yield; the other 3 pay no meaningful dividend
Best for: income & stability
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +110.4% vs IRBT's -97.7%
Best for: momentum
ALKS
Alkermes plc
The Growth Play

ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
  • -11.0% 10Y total return vs DBVT's -87.0%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
Best for: growth exposure and long-term compounding
IRBT
iRobot Corporation
The Secondary Option

IRBT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: consumer cyclical exposure
See the full category breakdown
CategoryWinnerWhy
GrowthALKS logoALKS-5.2% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs EKSO's -135.7%
Stability / SafetyALKS logoALKSBeta 1.06 vs IRBT's 5.21, lower leverage
DividendsEKSO logoEKSO0.8% yield; the other 3 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs IRBT's -97.7%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

EKSO vs DBVT vs ALKS vs IRBT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

EKSOEkso Bionics Holdings, Inc.
FY 2023
Product
77.3%$14M
Service
15.4%$3M
Subscription
5.3%$967,000
Product and Service, Other
2.0%$359,000
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
IRBTiRobot Corporation
FY 2024
Reportable Segment
100.0%$682M

EKSO vs DBVT vs ALKS vs IRBT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGEKSO

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to EKSO's -135.7%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricEKSO logoEKSOEkso Bionics Hold…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcIRBT logoIRBTiRobot Corporation
RevenueTrailing 12 months$12M$0$1.6B$547M
EBITDAEarnings before interest/tax-$14M-$112M$212M-$151M
Net IncomeAfter-tax profit-$16M-$168M$153M-$209M
Free Cash FlowCash after capex-$12M-$151M$392M-$107M
Gross MarginGross profit ÷ Revenue+52.9%+65.4%+22.0%
Operating MarginEBIT ÷ Revenue-134.1%+12.3%-29.5%
Net MarginNet income ÷ Revenue-135.7%+9.8%-38.2%
FCF MarginFCF ÷ Revenue-103.4%+25.1%-19.6%
Rev. Growth (YoY)Latest quarter vs prior year-36.6%+28.2%-24.6%
EPS Growth (YoY)Latest quarter vs prior year-17.5%+91.5%-4.1%-195.2%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

IRBT leads this category, winning 2 of 3 comparable metrics.
MetricEKSO logoEKSOEkso Bionics Hold…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcIRBT logoIRBTiRobot Corporation
Market CapShares × price$29M$1712.35T$5.9B$2M
Enterprise ValueMkt cap + debt − cash$30M$1712.35T$4.9B$95M
Trailing P/EPrice ÷ TTM EPS-2.40x-0.76x24.76x-0.01x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.25x
Price / SalesMarket cap ÷ Revenue2.24x4.00x0.00x
Price / BookPrice ÷ Book value/share3.17x0.66x3.28x0.03x
Price / FCFMarket cap ÷ FCF12.28x
IRBT leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-177 for EKSO. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRBT's 3.71x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs IRBT's 3/9, reflecting strong financial health.

MetricEKSO logoEKSOEkso Bionics Hold…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcIRBT logoIRBTiRobot Corporation
ROE (TTM)Return on equity-177.4%-130.2%+8.8%-112.9%
ROA (TTM)Return on assets-74.2%-89.0%+5.4%-43.3%
ROICReturn on invested capital-88.1%+18.9%-38.6%
ROCEReturn on capital employed-87.1%-145.7%+14.2%-27.7%
Piotroski ScoreFundamental quality 0–93473
Debt / EquityFinancial leverage0.29x0.13x0.04x3.71x
Net DebtTotal debt minus cash$1M-$172M-$1.0B$93M
Cash & Equiv.Liquid assets$1M$194M$1.1B$134M
Total DebtShort + long-term debt$3M$22M$70M$227M
Interest CoverageEBIT ÷ Interest expense-20.44x-189.82x32.30x-3.36x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $6 for IRBT. Over the past 12 months, DBVT leads with a +110.4% total return vs IRBT's -97.7%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs IRBT's -88.8% — a key indicator of consistent wealth creation.

MetricEKSO logoEKSOEkso Bionics Hold…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcIRBT logoIRBTiRobot Corporation
YTD ReturnYear-to-date+50.5%+4.9%+25.3%-55.0%
1-Year ReturnPast 12 months+79.3%+110.4%+16.5%-97.7%
3-Year ReturnCumulative with dividends-49.9%+19.7%+14.5%-99.9%
5-Year ReturnCumulative with dividends-85.5%-69.1%+60.9%-99.9%
10-Year ReturnCumulative with dividends-99.3%-87.0%-11.0%-99.9%
CAGR (3Y)Annualised 3-year return-20.6%+6.2%+4.6%-88.8%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than IRBT's 5.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs IRBT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricEKSO logoEKSOEkso Bionics Hold…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcIRBT logoIRBTiRobot Corporation
Beta (5Y)Sensitivity to S&P 5002.02x1.26x1.06x5.21x
52-Week HighHighest price in past year$13.50$26.18$36.60$6.10
52-Week LowLowest price in past year$2.73$7.53$25.17$0.04
% of 52W HighCurrent price vs 52-week peak+87.4%+76.3%+96.7%+0.9%
RSI (14)Momentum oscillator 0–10059.948.160.233.9
Avg Volume (50D)Average daily shares traded68K252K2.3M0
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: EKSO as "Buy", DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -49.2% for EKSO (target: $6). EKSO is the only dividend payer here at 0.79% yield — a key consideration for income-focused portfolios.

MetricEKSO logoEKSOEkso Bionics Hold…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcIRBT logoIRBTiRobot Corporation
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$6.00$46.33$44.00
# AnalystsCovering analysts41528
Dividend YieldAnnual dividend ÷ price+0.8%
Dividend StreakConsecutive years of raises000
Dividend / ShareAnnual DPS$0.09
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IRBT leads in 1 (Valuation Metrics).

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

EKSO vs DBVT vs ALKS vs IRBT: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is EKSO or DBVT or ALKS or IRBT a better buy right now?

For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.

2% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — EKSO or DBVT or ALKS or IRBT?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus IRBT's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — EKSO or DBVT or ALKS or IRBT?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus iRobot Corporation's 5. 21β — meaning IRBT is approximately 392% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — EKSO or DBVT or ALKS or IRBT?

By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.

2% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: iRobot Corporation grew EPS 55. 3% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — EKSO or DBVT or ALKS or IRBT?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — EKSO or DBVT or ALKS or IRBT?

In this comparison, EKSO (0.

8% yield) pays a dividend. DBVT, ALKS, IRBT do not pay a meaningful dividend and should not be held primarily for income.

07

Is EKSO or DBVT or ALKS or IRBT better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). iRobot Corporation (IRBT) carries a higher beta of 5. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between EKSO and DBVT and ALKS and IRBT?

These companies operate in different sectors (EKSO (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and IRBT (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

EKSO pays a dividend while DBVT, ALKS, IRBT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

EKSO

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 31%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

IRBT

Quality Business

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 13%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.